Oscar Health Aktie News

Wall Street loves to punish healthcare stocks for short-term stumbles while missing their revolutionary potential. The sector's reputation for regulatory complexity and unpredictable reimbursement changes has created a risk-averse investment environment that consistently undervalues companies building the future of American healthcare.

NEW YORK--(BUSINESS WIRE)--Oscar Health, Inc. (“Oscar” or the “Company”) (NYSE: OSCR), a leading healthcare technology company, announced today certain preliminary financial results for the second quarter ended June 30, 2025 and updates to full year 2025 guidance. The Company expects a loss from operations of approximately $230 million and a net loss of approximately $228 million for the second...

I rate Oscar Health as a buy, viewing short-term regulatory headwinds as a buying opportunity given its long-term growth prospects. Oscar's strong revenue growth, improving profitability, and efficient SG&A management support my positive outlook, despite recent bearish analyst coverage. The company's strategic expansion into the ICHRA market and deployment of AI technology are key drivers for f...

Key Points in This Article: Oscar Health's (OSCR) stock surged in June 2025 due to strong Q1 earnings but crashed after Centene's guidance withdrawal and analyst downgrades.

In this video, I will cover Oscar Health (OSCR -3.42%) and explain why investors should not panic, despite the stock being down 40% from its recent highs. Watch the short video to learn more, consider subscribing, and click the special offer link below.

Centene's $1.8B ACA risk shock triggered a ~15-20% drop in Oscar's stock but didn't alter Q1 fundamentals. Oscar posted 42% revenue growth, expanding to 2 million members with a record-low 15.8% SG&A expense ratio. Barclays' downgrade highlights policy risk, projecting over 100bps MLR pressure and aggressive EPS cuts if subsidies expire.

On July 2nd, the health insurance sector underwent a notable decline following Centene (NYSE:CNC)'s retraction of its financial outlook, citing rising costs. Refer to – Centene: Is The Recent Decline In CNC Stock Justified?

In this video, I explain why Oscar Health (OSCR -18.73%) crashed 18% on Wednesday and why I will buy shares. Watch the short video to learn more, consider subscribing, and click the special offer link below.